Peritoneal metastases in patients with neuroendocrine neoplasms: a challenging site of metastases with clinical and prognostic implications

• Published in: Journal of endocrinological investigation Vol. 47; no. 9; pp. 2295 - 2303
• Main Authors: Tsoli, M., Wilson, H., Armonis, P., Kamieniarz, L., Thuringer, J., Mirnezami, R., Caplin, M., Kaltsas, G., Toumpanakis, C.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2024; Springer Nature B.V
• Subjects: Adult; Aged; Endocrinology; Female; Follow-Up Studies; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Metastases; Metastasis; Middle Aged; Neuroendocrine system; Neuroendocrine tumors; Neuroendocrine Tumors - epidemiology; Neuroendocrine Tumors - pathology; Neuroendocrine Tumors - secondary; Neuroendocrine Tumors - therapy; Original Article; Patients; Peritoneal Neoplasms - epidemiology; Peritoneal Neoplasms - secondary; Peritoneal Neoplasms - therapy; Peritoneum; Prognosis; Quality of Life; Retrospective Studies; Small intestine; Somatostatin; Survival; Survival Rate; Neuroendocrine neoplasms; Peritoneal metastases; Prognosis
• ISSN: 1720-8386; 0391-4097; 1720-8386
• DOI: 10.1007/s40618-024-02330-5

Purpose Peritoneal metastases (PM) of neuroendocrine neoplasm (NEN) origin are identified with increasing frequency and exert a significant effect on quality of life and clinical status of the patients. The aim of this study was to identify the characteristics and the prognostic significance of PM in patients with NENs. Methods A retrospective analysis of the data of patients from two tertiary referral centers was performed. We defined a control group of age- and gender-matched NEN patients with comparable stage IV disease but no PM. Results We analysed 70 patients (41 females) with PM. Small intestine was the most common primary NEN site (87.1%). PM prevalence was 10.3%. Forty-four patients presented with synchronous PM, whereas 26 developed metachronous PM. The majority of patients had other concomitant metastases (50 hepatic, 6 lung and 12 bone metastases). Twelve patients developed intestinal obstruction. After PM diagnosis, 76% of patients received treatment with somatostatin analogues while six patients (8.6%) were treated with peptide receptor radionuclide therapy (PRRT). The median progression-free survival (PFS) in the PRRT-treated group was 15 months (95% CI 2–28). Median overall survival (OS) in the PM group was 142 months [95% CI 71–213] while it was not reached in the control group. Conclusion Peritoneal metastases show low prevalence among NEN patients and are most likely to develop in patients with small intestinal NENs and advanced metastatic disease. The presence of PM does seem to be associated with a negative prognostic impact on OS of NEN patients and their identification and prompt treatment is of major importance.